- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00728689
연구용 천연두 약물의 1상 시험
정상 건강한 지원자에서 항-오르토폭스바이러스 화합물 ST-246®의 형태 I 대 형태 V 캡슐의 단일 경구 투여량의 약동학에 대한 I상 무작위, 이중맹검, 교차, 탐색적 연구
The purpose of this study was to evaluate the pharmacokinetic parameters and safety of a single dose of ST-246 400mg Form I versus ST-246 400mg Form V capsules in fed normal healthy volunteers.
연구 개요
상세 설명
This was a Phase I, double-blind, cross-over, single-dose study of the orally administered anti-orthopoxvirus compound, ST-246, to 12 healthy, fed volunteers between the ages of 18 and 50 years. Subjects were randomized such that 6 subjects received either ST-246 Form I (monohydrate) followed 10 days later after a wash-out period by Form V (hemihydrate), and 6 subjects received ST-246 Form V followed by Form I, as for the previous group.
Both forms of ST-246 were similar in the way they were manufactured. The only difference between Form I and Form V may be related to how it dissolves, and this may affect the way that it is absorbed in the human body. Information about any side-effects that may occur will also be collected in this study.
연구 유형
등록 (실제)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
Florida
-
Orlando, Florida, 미국, 32809
- Orlando Clinical Research Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- 18 to 50 years
- Available for clinical follow-up duration of study.
- Able/willing to give written consent.
- Good general health; no clinically significant medical history.
- Refrain from taking any medications from screening through 72 hours after last dose.
- Adequate venous access.
- PE and lab results without clinically significant findings within 28 days prior to receipt of drug.
- Meet Lab Criteria within 28 days prior to receipt of drug.
- Negative pregnancy test
- Non smokers
- No alcohol or caffeine
- Participant or partner has undergone surgical sterilization, or the participant agrees either to be abstinent or use two non-hormonal methods of contraception for duration of the study
Exclusion Criteria:
-
Marked baseline prolongation of QT/corrected QT interval (QTc) interval (
-
History of additional risk factors for Torsade de Pointes
-
Clinically significant abnormal ECG
-
Personal history of cardiac disease, symptomatic or asymptomatic arrhythmias, syncopal episodes, or prolongation of the PR interval
-
Family history of Sudden Cardiac Death not clearly due to acute myocardial infarction.
-
History of any clinically significant conditions including:
- Asthma
- Diabetes mellitus
- History of thyroidectomy or thyroid disease
- Serious angioedema episodes
- Head trauma resulting in a diagnosis of TBI other than concussion
- Seizure or history of seizure
- Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with intramuscular injections or blood draws
- Malignancy
-
Family history of idiopathic seizures
-
History or presence of neutropenia or other blood dyscrasia
-
Known Hepatitis B or Hepatitis C infection
-
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome illness.
-
Current or recent history of a clinically significant bacterial, fungal, or mycobacterial infection.
-
Known clinically significant chronic viral infection (or current clinically significant viral infection
-
History of frequent or severe headaches or migraines
-
Known chronic bacterial, mycobacterial, fungal, parasitic, or protozoal infection
-
Woman who is pregnant or is breast-feeding or planning to become pregnant
-
On any concomitant medications
-
History of drug allergy that, in the opinion of the PI, contraindicates participation in the trial.
-
Inability to swallow medication
-
Body Mass Index above 35 or below 18,
-
Current drug abuse or alcohol abuse.
-
Inability to refrain from physical exercise for a period of 24 hr before and after a PK day or refrain from consuming xanthines, grapefruit or grapefruit juice
-
Clinically significant lactose intolerance
-
Received experimental drug within 30 days
-
Vaccination within 30 days
-
Total of more than 350 milliliters (mL) of blood drawn in 2 months
-
Treatment with any immunosuppressant or immunomodulatory medication in 3 months
-
Any condition occupational reason or other responsibility that, in the judgment of the PI, would jeopardize the safety or rights of a subject participating in the trial or would render the subject unable to comply with the protocol
-
History or diagnosis that would affect absorption of study medication
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 크로스오버 할당
- 마스킹: 삼루타
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Group ST-246 Form I (followed by Form V)
Each of six subjects receive a single oral 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single oral 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat. |
First Intervention is on Days 1 - 3, and includes 6 patients dosed once orally with ST-246 Form I (Arm 1), and 6 patients dosed once orally with ST-246 Form V (Arm 2).
다른 이름들:
Second Intervention is on Days 11 - 13 (after a 3 day post-treatment monitoring and 7 day wash-out period) where the 6 patients previously given ST-246 Form I (Arm 1) are now dosed once orally with ST-246 Form V, and the 6 patients previously given ST-246 Form V (Arm 2) are now dosed once orally with ST-246 Form I.
다른 이름들:
|
|
활성 비교기: Group ST-246 Form V (followed by Form I)
Each of six subjects receive a single oral 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single oral 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat. |
First Intervention is on Days 1 - 3, and includes 6 patients dosed once orally with ST-246 Form I (Arm 1), and 6 patients dosed once orally with ST-246 Form V (Arm 2).
다른 이름들:
Second Intervention is on Days 11 - 13 (after a 3 day post-treatment monitoring and 7 day wash-out period) where the 6 patients previously given ST-246 Form I (Arm 1) are now dosed once orally with ST-246 Form V, and the 6 patients previously given ST-246 Form V (Arm 2) are now dosed once orally with ST-246 Form I.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: t½
기간: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
Mean terminal half-life (t½; hrs) for Forms I and V were calculated from [plasma] vs time profiles. |
Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
|
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: AUC0-τ
기간: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
Area under the drug concentration-time curve from time zero to time t, where t is the last timepoint with a drug concentration ≥ lowest obtainable quantification (AUC0-τ; ng*hr/mL). |
Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
|
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: AUC0-∞
기간: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
Area under the drug concentration-time curve from time zero to infinity (AUC0-∞; ng*hr/mL). |
Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
|
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: Cmax
기간: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
Maximum drug concentration in plasma, determined directly from individual concentration-time data (Cmax) |
Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
|
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: Tmax
기간: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
Time to maximum plasma concentration(Tmax; hrs) for Forms I and V were calculated from [plasma] vs time profiles. |
Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of Study Participants Who Tolerated a Single Dose of ST-246 Form I vs. Form V as Determined by No Clinically Significant Changes in Safety Parameters
기간: 4 weeks
|
Evaluated safety parameters included:
|
4 weeks
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Thomas C Marbury, MD, Orlando Clinical Research Center
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정된)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- SIGA-246-005
- HHSN266200600014C (기타 보조금/기금 번호: NIAID)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .